S

Southern Clinical Research | Zachary, LA

Research site
(Unclaimed)
Location
4867 West Park Drive, Zachary, Louisiana, United States of America

Site insights

Top conditions

Top treatments

Obicetrapib
sodium
Selonsertib
BAY 2433334
GS-4997
Finerenone
Elinzanetant
Inclisiran
BAY3427080

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 14 total trials
Locations recently updated

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Enrolling
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Drug: Placebo in 1.5ml

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Obicetrapib
Drug: Placebo

The purpose of this study is to evaluate the growth and development outcomes of infants fed a new infant formula and toddler drink through 24 months...

Active, not recruiting
Growth
Other: Control Toddler Drink
Other: Control Infant Formula

The objective of this randomized, controlled trial is to evaluate the effects of consuming a pediatric oral nutritional supplement (ONS) plus dietary...

Enrolling
Undernutrition
Other: Oral Nutritional Supplement
Other: Dietary counseling

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying heterozygous familial hypercholester...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Dyslipidemias
Drug: Obicetrapib
Drug: Placebo

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Inclisiran sodium 300 mg

The purpose of this study is to evaluate the effect of finerenone compared to placebo (a tablet without active substance) in the reduction of cardiov...

Active, not recruiting
Heart Failure
Other: Placebo
Drug: Finerenone (BAY94-8862)

Trial sponsors

Bayer logo
Abbott logo
B
N
Novartis logo
Gilead Sciences logo
O
X

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems